Nathaniel Alvis
Family Medicine · Dunlap, IANPI 1861634008
Payments from drug & device makers
Across 410 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$883
- Lilly USA, LLC$658
- AstraZeneca$535
- Pfizer$418
- Amgen$388
- Mylan Specialty L.p.$349
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,495 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $243,416 |
| EliquisApixaban | 291 | $132,845 |
| MounjaroTirzepatide | 87 | $101,178 |
| XifaxanRifaximin | 27 | $86,698 |
| FarxigaDapagliflozin Propanediol | 120 | $46,594 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $43,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $40,455 |
| JardianceEmpagliflozin | 88 | $35,728 |
| TrulicityDulaglutide | 41 | $34,814 |
| MyrbetriqMirabegron | 104 | $32,247 |
| GemtesaVibegron | 85 | $21,514 |
| EntrestoSacubitril/Valsartan | 60 | $18,446 |
| VraylarCariprazine Hcl | 20 | $18,317 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $16,110 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $14,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $883 | $243,416246 claims |
| Lilly USA, LLCMounjaro, Trulicity | $658 | $135,992128 claims |
| PfizerEliquis | $418 | $132,845291 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $348 | $86,69827 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $83 | $66,883131 claims |
| AstraZenecaFarxiga, Lokelma | $535 | $59,272152 claims |
| AbbVieVraylar, Linzess, Viberzi, Lumigan | $280 | $46,33580 claims |
| Boehringer IngelheimJardiance, Tradjenta | $116 | $45,419109 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $32,247104 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $259 | $21,51485 claims |
| NovartisEntresto | $311 | $18,44660 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $110 | $16,11022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Dunlap
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.